Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy
NCT ID: NCT04909138
Last Updated: 2026-01-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-10-15
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study seeks to evaluate the use of intermittent dosing as an alternative paradigm for patients with DRG stimulation in place for at least 1 year and minimum 50% pain relief in the targeted area.
Patients will be prospectively randomized to one of two stimulation paradigms both of which involve intermittent dosing at 30 seconds ON and 90 seconds OFF. Group 1 will have their frequency set at 20 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation). Group 2 will have their frequency set at 5 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation) This study will be performed in a crossover fashion, meaning patients will be changed to the alternate dosing regimen at the 13-week time period.
Patients will be seen and evaluated prior to randomization and reprogramming, and thereafter evaluated at 4, 8, and 12-weeks. At the 12-week time period, patients will begin a 1-week washout period of continuous stimulation. At the 13-week time period, patients will be evaluated, crossed over to the other study arm and thereafter evaluated at 17, 21, and 25-weeks.
Patients will be prospectively randomized to one of two stimulation paradigms both of which involve intermittent dosing at 30 seconds ON and 90 seconds OFF. Group 1 will have their frequency set at 20 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation). Group 2 will have their frequency set at 5 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation) This study will be performed in a crossover fashion, meaning patients will be changed to the alternate dosing regimen at the 13-week time period.
Patients will be seen and evaluated prior to randomization and reprogramming, and thereafter evaluated at 4, 8, and 12-weeks. At the 12-week time period, patients will begin a 1-week washout period of continuous stimulation. At the 13-week time period, patients will be evaluated, crossed over to the other study arm and thereafter evaluated at 17, 21, and 25-weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TransGrade Multimodal Neuromodulation of the Dorsal Root Ganglion Ensemble for Refractory Neuropathic Pain
NCT03318250
Neuropathic Pain
Pain, Chronic
TERMINATED
NA
Sub-threshold DRG Stimulation vs Sham in Established Responders
NCT07170722
Neuropathic Pain
Complex Regional Pain Syndromes (CRPS)
Causalgia
+3 more
COMPLETED
NA
Trialing of ISS in Patients With CRPS
NCT03954080
CRPS I
Causalgia
COMPLETED
NA
BurstDR™ micrOdosing stimuLation in De-novo Patients
NCT03350256
Pain, Intractable
Pain, Back
COMPLETED
NA
Steroids Versus Gabapentin
NCT01495923
Sciatica
Radiculopathy
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Dorsal Root Ganglion (DRG) is a novel target of neuromodulation that's use has grown as a proven effective treatment in chronic painful conditions. Studies examining tonic, paresthesia-based dorsal column stimulation have demonstrated plateauing or diminishing effects after extended time periods. Although not yet studied in DRG stimulation due to its relative infancy, the possibility of decreased pain relief over time very much exists. In order to mitigate the potential for waning pain relief over time, other paradigms of stimulation within the framework of DRG therapy must be evaluated.
Intermittent dosing (ID) refers to the cycling of stimulation, in which there is a designated time period of stimulation being active (ON) and inactive (OFF). Previous studies have demonstrated the safe and effective use of intermittent dosing using spinal cord stimulation (SCS).9,10 In 2020, Deer et al. reported the efficacy of intermittent dosing of Burst stimulation with settings ranging from 30 seconds ON and 90 seconds OFF, to 30 seconds ON and 360 seconds OFF in SCS.10 However, no studies have examined the use of ID in DRG stimulation. Furthermore, a pre-clinical study by Chao et al. 2020 showed that DRG field stimulation delivered at 20 Hz continuously abated transmission of action potentials in most C-type fibers and 50% of Aδ fibers. Conversely, DRG field stimulation delivered at 5 Hz consistently evoked action potentials in Aβ, Aδ, and C type fibers, suggesting that this frequency may have greater potential to mitigate pain11. Nevertheless, translation of these results to clinical practice have yet to be studied.
Patients with chronic pain secondary to CRPS or other chronic neuropathic who have responded to DRG stimulation originally and have undergone permanent DRG stimulator implantation delivered by the Abbott PROCLAIM Dorsal Root Ganglion Neurostimulator System, have had the system in place for at least 1 year, utilizing continuous tonic therapy, reporting minimum 50% pain relief in the targeted area, will be randomized to 1 of 2 study arms, in a single-blinded, 1:1 fashion:
1. High ID Arm: DRG stimulation therapy at 20 Hz frequency for 30 seconds ON, 90 seconds OFF
2. Low ID Arm: DRG stimulation therapy at 5 Hz frequency for 30 seconds ON, 90 seconds OFF
Based on the stimulation frequency each patient receives the stimulation amplitude will be adjusted accordingly to remain in the therapeutic dosing window for each patient.
Patients will be seen and evaluated prior to randomization and reprogramming, and thereafter evaluated at 4, 8, and 12-weeks. At the 12-week time period, patients will begin a 1-week washout period of continuous stimulation at their pre-study stimulation settings. At the 13-week time period, patients will be evaluated, crossed over to the other study arm and thereafter evaluated at 17, 21, and 25-weeks.
As our primary endpoint, we hypothesize that intermittent dosing with either 20 Hz frequency (high) or 5 Hz frequency (low) ID will provide superior pain relief as measured by VAS scores when compared to continuous DRG stimulation therapy in this patient population. Other endpoints include: EQ-5D scores of wellbeing; PROMIS score for physical function, pain interference, sleep disturbance, and emotional distress; chronic pain acceptance questionnaire 8 (CPAQ-8), patient satisfaction scores, and patient global impression of change.
After evaluation, all eligible and consented subjects will be randomized into one of two treatment groups. Randomization will be performed using a computer-generated random sequence generator with equal selection probabilities to all groups. Subjects will be blinded to their randomization.
After randomization, each consented subject will present to clinic at which time will first be seen by a team of investigators, sub-investigators, and/or study staff. Patients will be sent for x-ray at initial presentation to evaluate for real-time DRG lead position. Patients will be excluded from study if there is significant migration, at the discretion of clinician. Patients will have had at least one prior attempted reprogramming in standard fashion (increasing amplitude firing in tonic stimulation to document stimulation is targeting dermatome of initial placement) before enrollment in this study. Otherwise, after evaluation and collection of baseline data, a clinical specialist for the Abbott PROCLAIM Dorsal Root Ganglion Neurostimulator System will program the subject's DRG system according to the treatment group to which they have been randomized, under direct physician supervision and with use of the radiographic films.
Patient will be subsequently evaluated at 4, 8 and 12 weeks. At the 12-week time interval, the patient will begin a 1-week washout period of continuous stimulation. At the 13-week time interval, the patient will be crossed over to the alternative study arm. Thereafter, they will be evaluated again at the 17-week, 21-week, and 25-week time interval. At each interval, the patient will be evaluated by a team of investigators, sub-investigators, and/or study staff to administer questionnaires and collect data.
Patient specific data to be collected prior to first allocated dosing stimulation will include:
* Age
* Height
* Weight
* BMI
* Gender
* Primary diagnosis
* Current daily morphine milligram equivalent usage
Data to be collected at baseline and at 12, 13 and 25 weeks of stimulation only:
* Patient Health Questionnaire (PHQ-8)
* PROMIS Health questionnaires
* Global Health 10 item questionnaire
* Physical Function 8b questionnaire
* Emotional Distress-8a Anxiety questionnaire
* Sleep Disturbance 4a questionnaire
* Fatigue 8 item questionnaire
* CPAQ-8 score (Chronic Pain Acceptance Questionnaire 8)
* Patient Global Impression of Change (see fig. 2)
* Patient Satisfaction Score (7-point Likert-type scale; see fig. 2)
Data to be collected at each study visit:
* NRS pain scores (22-point scale, 0-10 in 0.5 increments)
* Current dorsal root ganglion stimulation parameters (i.e. mode of stimulation-continuous vs. ID, frequency, amplitude, pulse width)
* Average charging frequency over last week
Risks \& Benefits:
As with all clinical research, there exists a potential for loss of confidentiality. Measure to protect the confidentiality of study participants will be implemented as described in the Data Collection \& Management Section Below.
Further loss of therapeutic pain relief is another potential risk that could occur following reprogramming to ID parameters. If at any point a subject reports diminishing pain relief and wishes to return to baseline mode of stimulation, they will be allowed to do so and considered a study failure. Patients would be encouraged to proceed with randomization process and if pain relief diminished, would be allowed to return to whichever desired mode of stimulation.
Subjects may experience benefit in the form of pain relief and improved functionality following reprogramming to ID parameters. However, if the patient chooses to no longer participate in the study, they may still receive treatment from the treating physician, which may include the ID parameters, administered separately, being investigated in this study.
Intermittent dosing (ID) refers to the cycling of stimulation, in which there is a designated time period of stimulation being active (ON) and inactive (OFF). Previous studies have demonstrated the safe and effective use of intermittent dosing using spinal cord stimulation (SCS).9,10 In 2020, Deer et al. reported the efficacy of intermittent dosing of Burst stimulation with settings ranging from 30 seconds ON and 90 seconds OFF, to 30 seconds ON and 360 seconds OFF in SCS.10 However, no studies have examined the use of ID in DRG stimulation. Furthermore, a pre-clinical study by Chao et al. 2020 showed that DRG field stimulation delivered at 20 Hz continuously abated transmission of action potentials in most C-type fibers and 50% of Aδ fibers. Conversely, DRG field stimulation delivered at 5 Hz consistently evoked action potentials in Aβ, Aδ, and C type fibers, suggesting that this frequency may have greater potential to mitigate pain11. Nevertheless, translation of these results to clinical practice have yet to be studied.
Patients with chronic pain secondary to CRPS or other chronic neuropathic who have responded to DRG stimulation originally and have undergone permanent DRG stimulator implantation delivered by the Abbott PROCLAIM Dorsal Root Ganglion Neurostimulator System, have had the system in place for at least 1 year, utilizing continuous tonic therapy, reporting minimum 50% pain relief in the targeted area, will be randomized to 1 of 2 study arms, in a single-blinded, 1:1 fashion:
1. High ID Arm: DRG stimulation therapy at 20 Hz frequency for 30 seconds ON, 90 seconds OFF
2. Low ID Arm: DRG stimulation therapy at 5 Hz frequency for 30 seconds ON, 90 seconds OFF
Based on the stimulation frequency each patient receives the stimulation amplitude will be adjusted accordingly to remain in the therapeutic dosing window for each patient.
Patients will be seen and evaluated prior to randomization and reprogramming, and thereafter evaluated at 4, 8, and 12-weeks. At the 12-week time period, patients will begin a 1-week washout period of continuous stimulation at their pre-study stimulation settings. At the 13-week time period, patients will be evaluated, crossed over to the other study arm and thereafter evaluated at 17, 21, and 25-weeks.
As our primary endpoint, we hypothesize that intermittent dosing with either 20 Hz frequency (high) or 5 Hz frequency (low) ID will provide superior pain relief as measured by VAS scores when compared to continuous DRG stimulation therapy in this patient population. Other endpoints include: EQ-5D scores of wellbeing; PROMIS score for physical function, pain interference, sleep disturbance, and emotional distress; chronic pain acceptance questionnaire 8 (CPAQ-8), patient satisfaction scores, and patient global impression of change.
After evaluation, all eligible and consented subjects will be randomized into one of two treatment groups. Randomization will be performed using a computer-generated random sequence generator with equal selection probabilities to all groups. Subjects will be blinded to their randomization.
After randomization, each consented subject will present to clinic at which time will first be seen by a team of investigators, sub-investigators, and/or study staff. Patients will be sent for x-ray at initial presentation to evaluate for real-time DRG lead position. Patients will be excluded from study if there is significant migration, at the discretion of clinician. Patients will have had at least one prior attempted reprogramming in standard fashion (increasing amplitude firing in tonic stimulation to document stimulation is targeting dermatome of initial placement) before enrollment in this study. Otherwise, after evaluation and collection of baseline data, a clinical specialist for the Abbott PROCLAIM Dorsal Root Ganglion Neurostimulator System will program the subject's DRG system according to the treatment group to which they have been randomized, under direct physician supervision and with use of the radiographic films.
Patient will be subsequently evaluated at 4, 8 and 12 weeks. At the 12-week time interval, the patient will begin a 1-week washout period of continuous stimulation. At the 13-week time interval, the patient will be crossed over to the alternative study arm. Thereafter, they will be evaluated again at the 17-week, 21-week, and 25-week time interval. At each interval, the patient will be evaluated by a team of investigators, sub-investigators, and/or study staff to administer questionnaires and collect data.
Patient specific data to be collected prior to first allocated dosing stimulation will include:
* Age
* Height
* Weight
* BMI
* Gender
* Primary diagnosis
* Current daily morphine milligram equivalent usage
Data to be collected at baseline and at 12, 13 and 25 weeks of stimulation only:
* Patient Health Questionnaire (PHQ-8)
* PROMIS Health questionnaires
* Global Health 10 item questionnaire
* Physical Function 8b questionnaire
* Emotional Distress-8a Anxiety questionnaire
* Sleep Disturbance 4a questionnaire
* Fatigue 8 item questionnaire
* CPAQ-8 score (Chronic Pain Acceptance Questionnaire 8)
* Patient Global Impression of Change (see fig. 2)
* Patient Satisfaction Score (7-point Likert-type scale; see fig. 2)
Data to be collected at each study visit:
* NRS pain scores (22-point scale, 0-10 in 0.5 increments)
* Current dorsal root ganglion stimulation parameters (i.e. mode of stimulation-continuous vs. ID, frequency, amplitude, pulse width)
* Average charging frequency over last week
Risks \& Benefits:
As with all clinical research, there exists a potential for loss of confidentiality. Measure to protect the confidentiality of study participants will be implemented as described in the Data Collection \& Management Section Below.
Further loss of therapeutic pain relief is another potential risk that could occur following reprogramming to ID parameters. If at any point a subject reports diminishing pain relief and wishes to return to baseline mode of stimulation, they will be allowed to do so and considered a study failure. Patients would be encouraged to proceed with randomization process and if pain relief diminished, would be allowed to return to whichever desired mode of stimulation.
Subjects may experience benefit in the form of pain relief and improved functionality following reprogramming to ID parameters. However, if the patient chooses to no longer participate in the study, they may still receive treatment from the treating physician, which may include the ID parameters, administered separately, being investigated in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
CRPS (Complex Regional Pain Syndromes)
Radiculopathy
Peripheral Neuropathy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Patients will be prospectively randomized to one of two stimulation paradigms both of which involve intermittent dosing at 30 seconds ON and 90 seconds OFF. Group 1 will have their frequency set at 20 Hz with amplitude set just below perception. Group 2 will have their frequency set at 5 Hz with amplitude set just below perception. This study will be performed in a crossover fashion with a washout period, meaning patients will receive one of the stimulation parameters at baseline, return to their pre-study stimulation settings at the 12-week time period and receive the alternate stimulation dosing regimen at the 13-week time period.
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Participants
Participants will not know to which treatment they are randomized
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DRG stimulation therapy at 20 Hz and 30 seconds ON, 90 seconds OFF
DRG stimulation therapy at 20 Hz (30 seconds ON, 90 seconds OFF)
Group Type
ACTIVE_COMPARATOR
DRG stimulation 20 Hz 30/90
Intervention Type
DEVICE
Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
DRG stimulation therapy at 5 Hz and 30 seconds ON, 90 seconds OFF
DRG stimulation therapy at 5 Hz (30 seconds ON, 90 seconds OFF)
Group Type
ACTIVE_COMPARATOR
DRG stimulation 5 Hz 30/90
Intervention Type
DEVICE
Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DRG stimulation 20 Hz 30/90
Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
Intervention Type
DEVICE
DRG stimulation 5 Hz 30/90
Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 99
* 1-year or more use of continuous DRG therapy as delivered a permanently implanted Abbott PROCLAIM XR Dorsal Root Ganglion Neurostimulator System for chronic back and/or leg pain
* Endorse at least 50% pain relief in the targeted area over the last year
* Must have been seen for routine follow-up within last 4 months
* Must have been reprogrammed in standard fashion at least once prior to randomization
* Willing and able to complete protocol requirements, including:
* Complete health questionnaires and pain scales as specified in the protocol
* Sign the study-specific informed consent form
* Complete follow-ups at the designated time periods
* 1-year or more use of continuous DRG therapy as delivered a permanently implanted Abbott PROCLAIM XR Dorsal Root Ganglion Neurostimulator System for chronic back and/or leg pain
* Endorse at least 50% pain relief in the targeted area over the last year
* Must have been seen for routine follow-up within last 4 months
* Must have been reprogrammed in standard fashion at least once prior to randomization
* Willing and able to complete protocol requirements, including:
* Complete health questionnaires and pain scales as specified in the protocol
* Sign the study-specific informed consent form
* Complete follow-ups at the designated time periods
Exclusion Criteria
* Significant lead migration, as determined by clinician
* Other concurrent neuromodulation system in place
* Corticosteroid injection in previous 30 days prior to enrollment
* Intermittent dosing and/or failure within last 6m
* Changing or unstable pain medications within 30 days
* Other concurrent neuromodulation system in place
* Corticosteroid injection in previous 30 days prior to enrollment
* Intermittent dosing and/or failure within last 6m
* Changing or unstable pain medications within 30 days
Minimum Eligible Age
18 Years
Maximum Eligible Age
90 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rush University Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandeep Amin, MD
Principal Investigator- Anesthesia Department (Provider)
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert McCarthy, PharmD
Role: STUDY_DIRECTOR
Rush University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, Amirdelfan K, Morgan DM, Brown LL, Yearwood TL, Bundschu R, Burton AW, Yang T, Benyamin R, Burgher AH. Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: The SENZA-RCT Randomized Controlled Trial. Anesthesiology. 2015 Oct;123(4):851-60. doi: 10.1097/ALN.0000000000000774.
Reference Type
BACKGROUND
Miller JP, Eldabe S, Buchser E, Johanek LM, Guan Y, Linderoth B. Parameters of Spinal Cord Stimulation and Their Role in Electrical Charge Delivery: A Review. Neuromodulation. 2016 Jun;19(4):373-84. doi: 10.1111/ner.12438. Epub 2016 May 6.
Reference Type
BACKGROUND
Deer T, Slavin KV, Amirdelfan K, North RB, Burton AW, Yearwood TL, Tavel E, Staats P, Falowski S, Pope J, Justiz R, Fabi AY, Taghva A, Paicius R, Houden T, Wilson D. Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform. Neuromodulation. 2018 Jan;21(1):56-66. doi: 10.1111/ner.12698. Epub 2017 Sep 29.
Reference Type
BACKGROUND
Alo KM, Redko V, Charnov J. Four Year Follow-up of Dual Electrode Spinal Cord Stimulation for Chronic Pain. Neuromodulation. 2002 Apr;5(2):79-88. doi: 10.1046/j.1525-1403.2002.02017.x.
Reference Type
BACKGROUND
Turner JA, Loeser JD, Deyo RA, Sanders SB. Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain syndrome: a systematic review of effectiveness and complications. Pain. 2004 Mar;108(1-2):137-47. doi: 10.1016/j.pain.2003.12.016.
Reference Type
BACKGROUND
Hayek SM, Veizi E, Hanes M. Treatment-Limiting Complications of Percutaneous Spinal Cord Stimulator Implants: A Review of Eight Years of Experience From an Academic Center Database. Neuromodulation. 2015 Oct;18(7):603-8; discussion 608-9. doi: 10.1111/ner.12312. Epub 2015 Jun 5.
Reference Type
BACKGROUND
Pope JE, Deer TR, Falowski S, Provenzano D, Hanes M, Hayek SM, Amrani J, Carlson J, Skaribas I, Parchuri K, McRoberts WP, Bolash R, Haider N, Hamza M, Amirdelfan K, Graham S, Hunter C, Lee E, Li S, Yang M, Campos L, Costandi S, Levy R, Mekhail N. Multicenter Retrospective Study of Neurostimulation With Exit of Therapy by Explant. Neuromodulation. 2017 Aug;20(6):543-552. doi: 10.1111/ner.12634. Epub 2017 Jul 17.
Reference Type
BACKGROUND
Van Buyten JP, Wille F, Smet I, Wensing C, Breel J, Karst E, Devos M, Poggel-Kramer K, Vesper J. Therapy-Related Explants After Spinal Cord Stimulation: Results of an International Retrospective Chart Review Study. Neuromodulation. 2017 Oct;20(7):642-649. doi: 10.1111/ner.12642. Epub 2017 Aug 18.
Reference Type
BACKGROUND
Vesper J, Slotty P, Schu S, Poeggel-Kraemer K, Littges H, Van Looy P, Agnesi F, Venkatesan L, Van Havenbergh T. Burst SCS Microdosing Is as Efficacious as Standard Burst SCS in Treating Chronic Back and Leg Pain: Results From a Randomized Controlled Trial. Neuromodulation. 2019 Feb;22(2):190-193. doi: 10.1111/ner.12883. Epub 2018 Nov 19.
Reference Type
BACKGROUND
Deer TR, Patterson DG, Baksh J, Pope JE, Mehta P, Raza A, Agnesi F, Chakravarthy KV. Novel Intermittent Dosing Burst Paradigm in Spinal Cord Stimulation. Neuromodulation. 2021 Apr;24(3):566-573. doi: 10.1111/ner.13143. Epub 2020 Mar 23.
Reference Type
BACKGROUND
Chao D, Zhang Z, Mecca CM, Hogan QH, Pan B. Analgesic dorsal root ganglionic field stimulation blocks conduction of afferent impulse trains selectively in nociceptive sensory afferents. Pain. 2020 Dec;161(12):2872-2886. doi: 10.1097/j.pain.0000000000001982.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21051403
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Dorsal Root Ganglion Stimulation in Postherpetic Neuropathy
NCT06225960
ENROLLING_BY_INVITATION
Focal Microvibration and Chronic Lumbosacral Radicular Pain
NCT06301061
NOT_YET_RECRUITING
NA
Comparative Study in Patients With Refractory Chronic Lower Limb Neuropathic Pain and/or Back Neuropathic Pain.
NCT04852107
TERMINATED
NA
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
NCT06306157
ENROLLING_BY_INVITATION
PHASE4
Efficacy Study of Botox to Treat Neuropathic Pain
NCT00527202
COMPLETED
PHASE4
Effects of Repetitive Electric Sensory Stimulation (RSS) as Intervention in Complex-regional-pain-syndrome Type I (CRPS)
NCT01915329
UNKNOWN
NA
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
NCT02502162
RECRUITING
NA
C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain
NCT02095197
COMPLETED
PHASE4
Theta Burst Brain Stimulation in Diabetic Neuropathy Patients With Neuropathic Pain: Investigating Neural Mechanisms
NCT04988321
COMPLETED
NA
Frequency of Piriformis Syndrome:Does the Presence of One Pathology Rule Out the Other?
NCT05450913
UNKNOWN
NA
Clinical Study Of a Micro-Implantable Pulse Generator For The Treatment of Peripheral Neuropathic Pain
NCT05287373
ACTIVE_NOT_RECRUITING
NA
Treatment of Shoulder Osteoarthritis
NCT05657587
UNKNOWN
Safety of Intravenous Neridronic Acid in CRPS
NCT02972359
COMPLETED
PHASE3
Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain
NCT06897280
ACTIVE_NOT_RECRUITING
PHASE4
Medtronic Inceptiv™ Closed-Loop DTM Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy
NCT07209514
ENROLLING_BY_INVITATION
NA
Pulsed Radiofrequency Therapy on Peripheral Nerves Monitoring Pain, Quality of Life, Patient Satisfaction and Efficacy
NCT06270940
RECRUITING
(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain
NCT05864053
RECRUITING
PHASE1/PHASE2
A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients
NCT06595004
COMPLETED
PHASE3
Ketamine HCl Prolonged Release Oral Tablets for CRPS
NCT06419985
NOT_YET_RECRUITING
PHASE2
Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS
NCT00579085
COMPLETED
PHASE2
A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury
NCT06091020
COMPLETED
PHASE2
Clinical Trial for Idiopathic Hip Pain Using Peripheral Nerve Stimulation
NCT05074329
UNKNOWN
NA
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
NCT03226574
COMPLETED
PHASE1
Stimgenics Open-Label, Post Market Study
NCT03606187
COMPLETED
NA
Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache
NCT03112720
TERMINATED
PHASE3